Avicanna Announces Warrant and Debenture Repricing and Amendments
January 30, 2023 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain
January 17, 2023 07:30 ET
|
Avicanna Inc.
This export marks Avicanna’s 19th new international market for Avicanna and the 16th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE...
Avicanna Announces Organizational Change in Avicanna LATAM S.A.S
December 30, 2022 07:30 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement
December 21, 2022 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product
December 14, 2022 07:33 ET
|
Avicanna Inc.
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
November 29, 2022 07:30 ET
|
Avicanna Inc.
Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC...
Avicanna Reports Q3 2022 Financial Statement
November 14, 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Avicanna Announces Closing of Non-Brokered Private Placement
November 11, 2022 07:30 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Extension of Term Loan
October 31, 2022 17:00 ET
|
Avicanna Inc.
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
October 20, 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...